Biocept, Inc. · OTC:BIOCQ

Biocept — Technical Presentation (April 2021)

7 slides from Biocept's technical presentation, April 2021

1. Slide 1: Detection of EGFR Mutations in Quantity Insufficient Tissue Slides by Target Selector

   1 Detection of EGFR Mutations in Quantity Insufficient Tissue Slides by High Sensitivity Assay Target SelectorTM in Patients with Non-Small Cell Lung Cancer Vassilios Alexiadis, PhD1., Jason Poole, PhD2., Veena Singh, MD1., Barbara Blouw, PhD1., Michael Dugan, MD1., Lawrence Weiss, MD3. 1Biocept, In

2. Slide 2: Introduction

   2 Introduction  Lung cancer is the leading cause of cancer-related death worldwide  The discovery of EGFR mutations and development of Tyrosine Kinase Inhibitors (TKIs) has a major improved clinical benefit over platinum-based therapies.  Historically, tissue biopsies are used for assessing the b

3. Slide 3: Switch Blocker Workflow

   3 Switch Blocker TM Workflow H&E Negative (N=6) Halt further analysis FFPE slides with insufficient quantity for NGS (N=12 H&E Evaluation unique NSCLC patients) H&E Positive (N=6) DNA Extraction Mutation Sequence qPCR Mutation Verification Detection CONFIDENTIAL

4. Slide 4: Switch Blocker Technology

   4 Switch BlockerTM Technology1 qPCR Mutation Forward Primer Q Switch F Anchor 5’ 3’ Detection of EGFR 3’ x Mutant Variants 5’ Mutation (up to 10 bp) Reverse Primer WT DNA Mutated DNA x Annealing Annealing Q Switch F Q F Switch Anchor Anchor 5’ 3’ 5’ x 3’ 3’ 3’ No Extension Extension 5’ 3’ Q F F Swit

5. Slide 5: Technology Identifies DNA in FFPE sections deemed QNS for Next-Gen Sequencing

   Switch Blocker TM Technology Identifies DNA in FFPE sections 5 deemed QNS for Next-Gen Sequencing Table 1. H&E Evaluation Results Table 2. EGFR WT Ct and Copy number Results Patient Number H&E Result Patient Number EGFR WT Total EGFR 1 Positive Ct Value copies 2 Positive 1 30.3 3184 3 Positive 2 30.

6. Slide 6: Technology Identifies Actionable Mutations in samples with insufficient amounts for NGS

   6 Switch Blocker TM Technology Identifies Actionable Mutations in samples with insufficient amounts for NGS Table 3. Results on EGFR and KRAS mutation detection in samples positive for H&E Patient Number Mutation Detected 1 None 2 Del19 3 L858R 4 None 5 KRAS G12V and L858R CONFIDENTIAL

7. Slide 7: Summary

   7 Summary  The Switch BlockerTM technology is a highly sensitive method that allows for the detection of mutations in specimens which are deemed QNS for NGS based assays.  This could lead to the ability to detect mutational changes in actionable biomarkers in patients that would otherwise not be c

Biocept — Technical Presentation (April 2021) on 6ix